SCHEIBLER LUKAS 4
4 · Apellis Pharmaceuticals, Inc. · Filed Apr 5, 2022
Insider Transaction Report
Form 4
SCHEIBLER LUKAS
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2022-04-04$13.85/sh+3,504$48,530→ 55,737 total - Sale
Common Stock
2022-04-04$56.86/sh−1,437$81,714→ 53,482 total - Sale
Common Stock
2022-04-04$57.80/sh−1,249$72,198→ 52,233 total - Sale
Common Stock
2022-04-04$55.84/sh−818$45,677→ 54,919 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-04-04−3,504→ 50,000 totalExercise: $13.85Exp: 2029-02-07→ Common Stock (3,504 underlying)
Footnotes (5)
- [F1]This is a scheduled exercise and sale from 10B5-1 trading plan.
- [F2]The sale price range within $1.00. Max. $55.21 - Min. $56.13
- [F3]The sale price range within $1.00. Max. $56.34 - Min. $57.22
- [F4]The sale price range within $1.00. Max. $57.37 - Min. $58.29.
- [F5]This represents a stock option grant made on 02/08/2019 that vests as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.